Extrusion 3D printing of minicaplets for evaluating in vitro &amp; in vivo praziquantel delivery capability

Bhatt, Ukti; Jorvekar, Sachin B; Murty, Upadhyayula Suryanarayana; Borkar, Roshan M.; Banerjee, Subham

doi:10.1016/j.ijpharm.2022.122445

Cited by 6 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An amount of 5.0 mL of sample aliquots was withdrawn at fixed time intervals, filtered to remove printed matrix debris, and further analyzed using the UV-visible spectrophotometer. The in vitro PCM release studies were performed in triplicate, and the cumulative amount of PCM released was determined as a function of time [23].…”

Section: In Vitro Pcm Release Studymentioning

confidence: 99%

Four-Dimensional Printed Construct from Temperature-Responsive Self-Folding Feedstock for Pharmaceutical Applications with Machine Learning Modeling

et al. 2023

Self Cite

View full text Add to dashboard Cite

Four-dimensional (4D) printing, as a newly evolving technology to formulate drug delivery devices, displays distinctive advantages that can autonomously monitor drug release according to the actual physiological circumstances. In this work, we reported our earlier synthesized novel thermo-responsive self-folding feedstock for possible SSE-mediated 3D printing to form a 4D printed construct deploying machine learning (ML) modeling to determine its shape recovery behavior followed by its potential drug delivery applications. Therefore, in the present study, we converted our earlier synthesized temperature-responsive self-folding (both placebo and drug-loaded) feedstock into 4D printed constructs using SSE-mediated 3D printing technology. Further, the shape memory programming of the printed 4D construct was achieved at 50 °C followed by shape fixation at 4 °C. The shape recovery was achieved at 37 °C, and the obtained data were used to train and ML algorithms for batch optimization. The optimized batch showed a shape recovery ratio of 97.41. Further, the optimized batch was used for the drug delivery application using paracetamol (PCM) as a model drug. The % entrapment efficiency of the PCM-loaded 4D construct was found to be 98.11 ± 1.5%. In addition, the in vitro release of PCM from this programmed 4D printed construct confirms temperature-responsive shrinkage/swelling properties via releasing almost 100% ± 4.19 of PCM within 4.0 h. at gastric pH medium. In summary, the proposed 4D printing strategy pioneers the paradigm that can independently control drug release with respect to the actual physiological environment.

show abstract

Section: In Vitro Pcm Release Studymentioning

confidence: 99%

Four-Dimensional Printed Construct from Temperature-Responsive Self-Folding Feedstock for Pharmaceutical Applications with Machine Learning Modeling

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, the choice of excipients used in these formulations was suitable for children. Additionally, the feasibility of using minitablets and minicaplets tailored for pediatric patients was explored, providing an alternative to conventional oral solid dosage forms with sizes conducive to easy swallowing [ 114 , 115 ]. Although a wide range of dosage forms can be developed using SSE, the most promising ones to be implemented in clinical practice are chewable tablets.…”

Section: Navigating Metabolic Mazes: Pioneering Precision Medicine In...mentioning

confidence: 99%

3D Printing of Dietary Products for the Management of Inborn Errors of Intermediary Metabolism in Pediatric Populations

Carou-Senra,

Rodríguez-Pombo,

Monteagudo-Vilavedra

et al. 2023

Nutrients

View full text Add to dashboard Cite

The incidence of Inborn Error of Intermediary Metabolism (IEiM) diseases may be low, yet collectively, they impact approximately 6–10% of the global population, primarily affecting children. Precise treatment doses and strict adherence to prescribed diet and pharmacological treatment regimens are imperative to avert metabolic disturbances in patients. However, the existing dietary and pharmacological products suffer from poor palatability, posing challenges to patient adherence. Furthermore, frequent dose adjustments contingent on age and drug blood levels further complicate treatment. Semi-solid extrusion (SSE) 3D printing technology is currently under assessment as a pioneering method for crafting customized chewable dosage forms, surmounting the primary limitations prevalent in present therapies. This method offers a spectrum of advantages, including the flexibility to tailor patient-specific doses, excipients, and organoleptic properties. These elements are pivotal in ensuring the treatment’s efficacy, safety, and adherence. This comprehensive review presents the current landscape of available dietary products, diagnostic methods, therapeutic monitoring, and the latest advancements in SSE technology. It highlights the rationale underpinning their adoption while addressing regulatory aspects imperative for their seamless integration into clinical practice.

show abstract

“…This unique capability opens up new avenues for drug delivery applications, including the development of transdermal patches. [8][9][10][11] Additionally, the precise control over the geometry and internal structure provided by 3D bioprinting allows for the customization of transdermal patches to suit individual patient needs. [12][13][14][15] Tailoring the patch design to match the patient's anatomy can improve the adherence of the patch to the skin, enhance drug permeation, and increase overall patient comfort.…”

mentioning

confidence: 99%

Generation of HPMC-derived Placebo Hydrogel Component Matrix System for Possible Pharmaceutical 3D Printing Applications

Nikhilesh

2023

IJHTI

View full text Add to dashboard Cite

Integration of 3D bioprinting technology in the design and fabrication of pharmaceutical dosage form has the potential toovercome the limitations and expand the range of drugs that can be delivered through different routes. In recent years, thefield of bioprinting has emerged as a revolutionary technology with the potential to transform various aspects of the healthcareand pharmaceutical industries. Among its wide-ranging applications, one of the most promising areas is the development oftransdermal drug delivery systems using 3D bioprinting techniques. This innovative approach holds significant promise inenhancing drug delivery efficiency, improving patient compliance, and revolutionizing personalized medicine. 3D bioprintingtechnology offers exciting prospects for the development of transdermal patches specifically designed for wound healingapplications. With further advancements and research, these innovative patches have the potential to revolutionize the fieldof wound care and improve patient outcomes.

show abstract

Extrusion 3D printing of minicaplets for evaluating in vitro & in vivo praziquantel delivery capability

Cited by 6 publications

References 27 publications

Four-Dimensional Printed Construct from Temperature-Responsive Self-Folding Feedstock for Pharmaceutical Applications with Machine Learning Modeling

Four-Dimensional Printed Construct from Temperature-Responsive Self-Folding Feedstock for Pharmaceutical Applications with Machine Learning Modeling

3D Printing of Dietary Products for the Management of Inborn Errors of Intermediary Metabolism in Pediatric Populations

Generation of HPMC-derived Placebo Hydrogel Component Matrix System for Possible Pharmaceutical 3D Printing Applications

Contact Info

Product

Resources

About